20,696 Royalty Pharma PLC $RPRX Shares Acquired by Profund Advisors LLC

Profund Advisors LLC increased its position in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 445.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 25,344 shares of the biopharmaceutical company’s stock after acquiring an additional 20,696 shares during the quarter. Profund Advisors LLC’s holdings in Royalty Pharma were worth $1,479,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Calamos Wealth Management LLC purchased a new position in shares of Royalty Pharma during the 1st quarter worth $3,762,000. Monetta Financial Services Inc. acquired a new stake in shares of Royalty Pharma during the second quarter worth $1,682,000. TD Waterhouse Canada Inc. boosted its holdings in shares of Royalty Pharma by 121.2% during the second quarter. TD Waterhouse Canada Inc. now owns 81,697 shares of the biopharmaceutical company’s stock worth $4,564,000 after purchasing an additional 44,764 shares during the last quarter. Dorsey Asset Management LLC grew its position in shares of Royalty Pharma by 0.8% in the first quarter. Dorsey Asset Management LLC now owns 2,276,570 shares of the biopharmaceutical company’s stock valued at $109,207,000 after purchasing an additional 17,101 shares during the period. Finally, NewEdge Advisors LLC grew its position in shares of Royalty Pharma by 400.2% in the second quarter. NewEdge Advisors LLC now owns 21,597 shares of the biopharmaceutical company’s stock valued at $1,211,000 after purchasing an additional 17,279 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on RPRX. TD Cowen upped their target price on Royalty Pharma from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. Weiss Ratings raised Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, September 14th. Wall Street Zen cut Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 26th. Morgan Stanley upped their price objective on shares of Royalty Pharma from $65.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Finally, Bank of America reiterated a “buy” rating on shares of Royalty Pharma in a report on Wednesday, August 5th. Eight analysts have rated the stock with a Buy rating. According to MarketBeat.com, Royalty Pharma has a consensus rating of “Buy” and a consensus target price of $61.57.

Insider Transactions at Royalty Pharma

In other news, EVP Christopher Hite sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total value of $5,853,000.00. Following the transaction, the executive vice president directly owned 270,401 shares in the company, valued at $15,826,570.53. This trade represents a 27.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of the firm’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $57.10, for a total value of $235,594.60. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 208,252 shares of company stock valued at $12,324,407. 18.84% of the stock is owned by company insiders.

Royalty Pharma Stock Down 1.0%

Shares of RPRX opened at $66.52 on Tuesday. Royalty Pharma PLC has a fifty-two week low of $36.03 and a fifty-two week high of $67.71. The company’s fifty day moving average is $60.38 and its two-hundred day moving average is $53.26. The firm has a market cap of $38.25 billion, a PE ratio of 45.88, a price-to-earnings-growth ratio of 1.78 and a beta of 0.42. The company has a quick ratio of 2.80, a current ratio of 2.80 and a debt-to-equity ratio of 0.88.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.05. The business had revenue of $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. Analysts forecast that Royalty Pharma PLC will post 5.29 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a $0.2350 dividend. The ex-dividend date is Friday, November 13th. This represents a $0.94 dividend on an annualized basis and a yield of 1.4%. Royalty Pharma’s dividend payout ratio (DPR) is presently 64.83%.

Royalty Pharma Profile

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.